AVBP Stock Forecast & Price Target

ArriVent BioPharma is attractive because its lead drug firmonertinib is targeting underserved EGFR-mutant NSCLC populations, where Phase 1b data already showed strong efficacy with 78.6% ORR and 15.2-month duration of response in exon 20 insertion disease, plus 68% confirmed ORR and 16.0-month PFS in PACC. The pivotal Phase 3 FURVENT readout expected in 2H26 is the main catalyst, and the trial’s design, prior event-accrual progress, and favorable control-arm context support a constructive view that the company may deliver a clinically meaningful PFS advantage. Financially, ArriVent ended 2Q26 with $373.1 million in cash and cash equivalents, a runway into 2028, while pipeline programs such as ALPACCA, ARR-217, and ARR-002 add long-term upside beyond the near-term readout.

ArriVent BioPharma is facing a deteriorating fundamental setup because FURVENT’s readout has slipped to 2H26 after the required event count was still not reached, and the added 4-6 weeks for database lock, cleaning, and QC only extends uncertainty. The thesis is further weakened by the view that control-arm benchmarks from WU-KONG28 and EXCLAIM-2 make it unlikely the delay is driven by the comparator, implying the firmo arm may be underperforming relative to expectations and jeopardizing a statistically significant PFS result. If FURVENT posts <8 months PFS, Ex20ins adoption could stay below 15% in the U.S., while softer PACC durability, weaker ALPACCA separation, competitive pressure, and possible dilutive financing all point to reduced peak sales and higher execution risk.